Proactive Investors
03 Aug 2026, 06:31 UTC · 1h ago
CelLBxHealth study detects drug targets on cancer cells rivals would miss
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
03 Aug 2026, 06:31 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
An independent study published in The Journal of Liquid Biopsy shows CellBXHealth's Parsortix system can detect biological targets for cancer drugs on cells that rival platforms would miss. — Demonstrating a technical superiority over competitors in a peer-reviewed study provides a significant catalyst for adoption in the $17 billion antibody-drug conjugate market.
+0.60BTC Company Ltd has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 g/t gold. — High-grade surface samples at a new project provide positive early-stage exploration data, though they do not yet prove a commercial deposit.
+0.40Which stocks this story touches
An independent peer-reviewed study showed its Parsortix system can detect biological targets for cancer drugs, outperforming rival platforms.
Continue reading
6 related stories
Search tags
The company has staked 36 mineral claims at a new project with surface samples returning significant gold levels.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
6h ago
